Kaname Yamamoto

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model

Chinami Masuda, Mieko Yanagisawa, Keigo Yorozu et al. · International Journal of Oncology · 2017 · 82 citations · Full text

Pathology, Pharmacotherapy, Cancer Biology +16

Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies

Toshiki Iwai, Masamichi Sugimoto, Daiko Wakita et al. · Oncotarget · 2018 · 74 citations · Full text

Human placenta gangliosides

Takao Taki, Kenichi Matsuo, Kaname Yamamoto et al. · Lipids · 1988 · 46 citations

Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade

Daiko Wakita, Toshiki Iwai, Suguru Harada et al. · Anticancer Research · 2019 · 42 citations · Full text

Impact of bevacizumab in combination with erlotinib on <scp><i>EGFR</i></scp>‐mutated non–small cell lung cancer xenograft models with <scp>T790M</scp> mutation or <scp><i>MET</i></scp> amplification

Koh Furugaki, Junko Fukumura, Toshiki Iwai et al. · International Journal of Cancer · 2015 · 38 citations